The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Analytical Methods
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The common CQAs to be monitored include process‐related impurities such as host cell proteins (HCP) and nucleic acids, as well as product‐related impurities such as higher and lower molecular weight species (HMW, LMW) and charge variants [34].”
From Current PAT Landscape in the Downstream Processing of Biopharmaceuticals (2025) · cites this paper as [34]
Citations
Cites
Esmonde-White, K. A., Cuellar, M., Uerpmann, C., Lenain, B., & Lewis, I. R. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9824-1 · Cited by 332
Rogers, R. S., Nightlinger, N. S., Livingston, B., Campbell, P., Bailey, R., & Balland, A. (2015) · mAbs · doi:10.1080/19420862.2015.1069454 · Cited by 231
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Middaugh, C. R., & Winter, G. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21989 · Cited by 202
Research works printed but not linked: 62
- Kirschner, 2008, GLYCAM06: a generalizable biomolecular force field. Carbohydrates, J. Comput. Chem., 29, 622, 10.1002/jcc.20820 · DOI · Paper page
- Underwood, 2010, Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor, J. Biol. Chem., 285, 723, 10.1074/jbc.M109.033829 · DOI · Paper page
- Walsh, 2005, Protein posttranslational modifications: the chemistry of proteome diversifications, Angew. Chem. Int. Ed. Engl., 44, 7342, 10.1002/anie.200501023 · DOI · Paper page
- Patel, 2011, Stability considerations for biopharmaceuticals, Part 1: overview of protein and peptide degradation pathways, BioProcess Int., 9, 20
- Beck, 2013, Characterization of therapeutic antibodies and related products, Anal. Chem., 85, 715, 10.1021/ac3032355 · DOI · Paper page
- Bayry, 2007, Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action, Nat. Clin. Pract. Rheumatol., 3, 262, 10.1038/ncprheum0481 · DOI
- Haberger, 2014, Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes, MAbs, 6, 327, 10.4161/mabs.27876 · DOI · Paper page
- Abdiche, 2008, Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet, Anal. Biochem., 377, 209, 10.1016/j.ab.2008.03.035 · DOI · Paper page
- Mora, 2010, Application of the Gyrolab platform to ligand-binding assays: a user’s perspective, Bioanalysis, 2, 1711, 10.4155/bio.10.122 · doi:10.4155/bio.10.122
- Segel, 1975, vol. 957
- Bielefeld-Sevigny, 2009, AlphaLISA immunoassay platform- the “no-wash” high-throughput alternative to ELISA assay, Drug Dev. Technol., 7, 90, 10.1089/adt.2009.9996 · DOI
- Wang, 2009, Host cell proteins in biologics development: Identification, quantitation and risk assessment, Biotechnol. Bioeng., 103, 446, 10.1002/bit.22304 · DOI · Paper page
- Champion, 2005, Defining your product profile and maintaining control over it, part 2, BioProcess Int., 3, 52
- Bracewell, 2015, The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control, Biotechnol. Bioeng., 112, 1727, 10.1002/bit.25628 · DOI · Paper page
- Doneanu, 2012, Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry, MAbs, 4, 24, 10.4161/mabs.4.1.18748 · DOI · Paper page
- Schenauer, 2012, Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry, Anal. Biochem., 428, 150, 10.1016/j.ab.2012.05.018 · DOI
- Zhang, 2013, Protein analysis by shotgun/bottom-up proteomics, Chem. Rev., 113, 2343, 10.1021/cr3003533 · DOI · Paper page
- Yang, 2010, A probabilistic model for risk assessment of residual host cell DNA in biological products, Vaccine, 28, 3308, 10.1016/j.vaccine.2010.02.099 · DOI
- Singer, 1997, Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation, Anal. Biochem., 249, 228, 10.1006/abio.1997.2177 · DOI · Paper page
- Rosenberg, 2006, Effects of protein aggregates: an immunologic perspective, AAPS J., 8, E501, 10.1208/aapsj080359 · DOI · Paper page
- Fekete, 2014, Theory and practice of size exclusion chromatography for the analysis of protein aggregates, J. Pharm. Biomed. Anal., 101, 161, 10.1016/j.jpba.2014.04.011 · DOI · Paper page
- Hong, 2012, A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates, J. Liq. Chromatogr. Relat. Technol., 35, 2923, 10.1080/10826076.2012.743724 · DOI · Paper page
- Ejima, 2005, Arginine as an effective additive in gel permeation chromatography, J. Chromatogr. A, 1094, 49, 10.1016/j.chroma.2005.07.086 · DOI
- Ricker, 1996, Fast, reproducible size-exclusion chromatography of biological macromolecules, J. Chromatogr. A, 743, 43, 10.1016/0021-9673(96)00283-X · DOI
- Patel, 2011, Stability considerations for biopharmaceuticals, Part 1: overview of protein and peptide degradation pathways, BioProcess Int., 9, 20
- Harris, 2001, Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B Biomed. Sci. Appl., 752, 233, 10.1016/S0378-4347(00)00548-X · DOI · Paper page
- Meert, 2010, Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients, Anal. Chem., 82, 3510, 10.1021/ac902408r · DOI
- Sosic, 2008, Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity, Electrophoresis, 29, 4368, 10.1002/elps.200800157 · DOI
- Staub, 2011, Intact protein analysis in the biopharmaceutical field, J. Pharm. Biomed. Anal., 55, 810, 10.1016/j.jpba.2011.01.031 · DOI · Paper page
- Zhao, 2014, Applications of capillary electrophoresis in characterizing recombinant protein therapeutics, Electrophoresis, 35, 96, 10.1002/elps.201300372 · DOI
- Ambrogelly, 2012, Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide, MAbs, 4, 701, 10.4161/mabs.21614 · DOI
- Kotia, 2010, Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide, Anal. Biochem., 399, 190, 10.1016/j.ab.2010.01.008 · doi:10.1016/j.ab.2010.01.008
- Petersen, 2011, SignalP 4.0: discriminating signal peptides from transmembrane regions, Nat. Methods, 8, 785, 10.1038/nmeth.1701 · DOI · Paper page
- Dick, 2008, C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes, Biotechnol. Bioeng., 100, 1132, 10.1002/bit.21855 · DOI
- Harris, 2014, Amino acid misincorporation in recombinant biopharmaceutical products, Curr. Opin. Biotechnol., 30, 45, 10.1016/j.copbio.2014.05.003 · DOI
- Zhang, 2013, G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations, Biochemistry, 52, 8165, 10.1021/bi401002c · DOI
- Traylor, 2016, Comprehensive discovery and quantitation of protein heterogeneity via LC-MS/MS peptide mapping for clone selection of a therapeutic protein, Anal. Chem., 88, 9309, 10.1021/acs.analchem.6b02895 · DOI
- Li, 2009, Pharmacological significance of glycosylation in therapeutic proteins, Curr. Opin. Biotechnol., 20, 678, 10.1016/j.copbio.2009.10.009 · DOI · Paper page
- Anumula, 2006, Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates, Anal. Biochem., 350, 1, 10.1016/j.ab.2005.09.037 · DOI · Paper page
- Beck, 2008, Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins, Curr. Pharm. Biotechnol., 9, 482, 10.2174/138920108786786411 · DOI · Paper page
- Harazono, 2011, A comparative study of monosaccharide composition analysis as a carbohydrate test for biopharmaceuticals, Biologicals, 39, 171, 10.1016/j.biologicals.2011.04.002 · doi:10.1016/j.biologicals.2011.04.002
- Stockert, 1995, The asialoglycoprotein receptor: relationships between structure, function, and expression, Physiol. Rev., 75, 591, 10.1152/physrev.1995.75.3.591 · DOI · Paper page
- Lis, 1998, Lectins: carbohydrate-specific proteins that mediate cellular recognition, Chem. Rev., 98, 637, 10.1021/cr940413g · DOI · Paper page
- Shah, 2014, LC-MS/MS peptide mapping with automated data processing for routine profiling of N-glycans in immunoglobulins, J. Am. Soc. Mass Spectrom., 25, 999, 10.1007/s13361-014-0858-3 · DOI
- Dong, 2016, A high-throughput, automated protein a purification platform with multi-attribute LC-MS analysis for advanced cell culture process monitoring, Anal. Chem., 88, 8673, 10.1021/acs.analchem.6b01956 · DOI
- Narhi, 2013, vol. 4
- Wei, 2014, Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications, Drug Discov. Today, 19, 95, 10.1016/j.drudis.2013.07.019 · DOI · Paper page
- Amezcua, 2013, Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy, J. Pharm. Sci., 102, 1724, 10.1002/jps.23531 · doi:10.1002/jps.23531
- Ghasriani, 2016, Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars, Nat. Biotechnol., 34, 139, 10.1038/nbt.3474 · doi:10.1038/nbt.3474
- Brooks, 2004, Appropriate glycosylation of recombinant proteins for human use, Mol. Biotechnol., 28, 241, 10.1385/MB:28:3:241 · DOI · Paper page
- Hamilton, 2007, Glycosylation engineering in yeast: the advent of fully humanized yeast, Curr. Opin. Biotechnol., 18, 387, 10.1016/j.copbio.2007.09.001 · DOI · Paper page
- Durocher, 2009, Expression systems for therapeutic glycoprotein production, Curr. Opin. Biotechnol., 20, 700, 10.1016/j.copbio.2009.10.008 · DOI · Paper page
- Chung, 2008, Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose, N. Engl. J. Med., 358, 1109, 10.1056/NEJMoa074943 · DOI · Paper page
- Borys, 2010, Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells, Biotechnol. Bioeng., 105, 1048, 10.1002/bit.22644 · DOI
- Noguchi, 1995, Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells, J. Biochem., 117, 59, 10.1093/oxfordjournals.jbchem.a124721 · DOI
- Padler-Karavani, 2008, Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease, Glycobiology, 18, 818, 10.1093/glycob/cwn072 · DOI · Paper page
- Tangvoranuntakul, 2003, Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid, Proc. Natl. Acad. Sci. U. S. A., 100, 12045, 10.1073/pnas.2131556100 · DOI · Paper page
- Jung, 2011, Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy, Curr. Opin. Biotechnol., 22, 858, 10.1016/j.copbio.2011.03.002 · DOI
- Chirino, 2004, Minimizing the immunogenicity of protein therapeutics, Drug Discov. Today, 9, 82, 10.1016/S1359-6446(03)02953-2 · DOI · Paper page
- Schellekens, 2002, Immunogenicity of therapeutic proteins: clinical implications and future prospects, Clin. Ther., 24, 1720, 10.1016/S0149-2918(02)80075-3 · DOI · Paper page
- Schellekens, 2003, Immunogenicity of therapeutic proteins, Nephrol. Dial. Transplant., 18, 1257, 10.1093/ndt/gfg164 · DOI
- Rathore, 2008, Case study and application of process analytical technology (PAT) towards bioprocessing: Use of on‐line high‐performance liquid chromatography (HPLC) for making real‐time pooling decisions for process chromatography, Biotechnol. Bioeng., 100, 306, 10.1002/bit.21759 · DOI
Cited by
Gimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
Current PAT Landscape in the Downstream Processing of Biopharmaceuticals
Sathiyapriyan, P., Mukherjee, S., Vogel, T., Essen, L., Boerema, D., Vey, M., & Kalina, U. (2025) · Analytical Science Advances · doi:10.1002/ansa.70013 · Cited by 45
Metadata
- Authors
- Traylor, M. J., Bernhardt, P., Tangarone, B. S., & Varghese, J.
- Venue
- Biopharmaceutical Processing
- Publisher
- Elsevier
- Published
- 2018
- Pages
- 1001-1049
- Cited by
- 1
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analytical Methods. https://app.cochat.ai/papers/10.1016/b978-0-08-100623-8.00047-5
- The paper
- Traylor, M. J., Bernhardt, P., Tangarone, B. S., & Varghese, J. (2018). Analytical Methods. Biopharmaceutical Processing. https://doi.org/10.1016/b978-0-08-100623-8.00047-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.